Menu Search

The Biotech Growth Trust PLC

BIOG:LSE

The Biotech Growth Trust PLC

Actions
  • Price (GBX)778.00
  • Today's Change-2.00 / -0.26%
  • Shares traded116.68k
  • 1 Year change-23.12%
  • Beta0.4662
Data delayed at least 20 minutes, as of Jul 11 2025 16:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year The Biotech Growth Trust PLC's revenues fell -- from 79.73m to -77.53m. has gone from a gain of 74.60m to a loss of 82.66m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-25.91%
Return on equity-28.38%
Return on investment-28.38%
More ▼

Cash flow in GBPView more

In 2025, The Biotech Growth Trust PLC increased its cash reserves by 296.67%, or 6.32m. Cash Flow from Investing totalled 115.85m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 5.09m for operations while cash used for financing totalled 104.29m.
Cash flow per share--
Price/Cash flow per share--
Book value per share8.16
Tangible book value per share8.16
More ▼

Balance sheet in GBPView more

The Biotech Growth Trust PLC has little financial risk as the capital structure does not rely on leverage.
Current ratio1.56
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items dropped -226.72%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-226.69
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.